Advertisement

Topics

Alexion Release: Interim Analysis From Phase III Open-Label Extension Study Shows Sustained Benefits Of Soliris (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

20:00 EDT 13 Sep 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Alexion Release: Interim Analysis From Phase III Open-Label Extension Study Shows Sustained Benefits Of Soliris (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

NEXT ARTICLE

More From BioPortfolio on "Alexion Release: Interim Analysis From Phase III Open-Label Extension Study Shows Sustained Benefits Of Soliris (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis"

Quick Search
Advertisement